Interfering metabolic pathways contributing to undesirable effects related to the PNPLA3 I148M variant (such as HSD17B13 inhibition) is another promising approach to counteract the NAFLD burden [139]. Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.